相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Src family kinases, HCK and FGR, associate with local inflammation and tumour progression in colorectal cancer
Antonia K. Roseweir et al.
CELLULAR SIGNALLING (2019)
c-Src is required for hypoxia-induced metastasis-associated functions in prostate cancer cells
Yao Dai et al.
ONCOTARGETS AND THERAPY (2019)
Targeting Tyrosine Kinases in Cancer: Lessons for an Effective Targeted Therapy in the Clinic
Adriano Angelucci
CANCERS (2019)
Predictive Biomarkers of Response to Src Inhibitors in Lung Cancer Getting to YES1
Howard Y. Li et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib
Irati Garmendia et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
PTPN3 suppresses lung cancer cell invasiveness by counteracting Src-mediated DAAM1 activation and actin polymerization
Meng-Yen Li et al.
ONCOGENE (2019)
EGFR-c-Src-Mediated HDAC3 Phosphorylation Exacerbates Invasion of Breast Cancer Cells
Sung-Min Kwak et al.
CELLS (2019)
Leptin Promotes Expression of EMT-Related Transcription Factors and Invasion in a Src and FAK-Dependent Pathway in MCF10A Mammary Epithelial Cells
Monserrat Olea-Flores et al.
CELLS (2019)
Personalized Cancer Therapy: YES1 Is the New Kid on the Block
Kunal Rai
CANCER RESEARCH (2019)
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study
Alberto Ocana et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results
Dana B. Cardin et al.
INVESTIGATIONAL NEW DRUGS (2018)
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer
Shumei Kato et al.
INVESTIGATIONAL NEW DRUGS (2018)
Src nuclear localization and its prognostic relevance in human osteosarcoma
Enrica Urciuoli et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2018)
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424
Victoria K. Woodcock et al.
BRITISH JOURNAL OF CANCER (2018)
c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin invitro and invivo
Longquan Lou et al.
CANCER SCIENCE (2018)
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
Patrick G. Morris et al.
CLINICAL BREAST CANCER (2018)
Src- and confinement-dependent FAK activation causes E-cadherin relaxation and beta-catenin activity
Charlene Gayrard et al.
JOURNAL OF CELL BIOLOGY (2018)
c-Src activity is differentially required by cancer cell motility modes
Jeremy S. Logue et al.
ONCOGENE (2018)
Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer
Thomas C. Beadnell et al.
ONCOGENESIS (2018)
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib
Scott M. Schuetze et al.
JAMA ONCOLOGY (2018)
SRC inhibition prevents P-cadherin mediated signaling and function in basal-like breast cancer cells
Ana Sofia Ribeiro et al.
CELL COMMUNICATION AND SIGNALING (2018)
Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells
Giusy Tornillo et al.
CELL REPORTS (2018)
Src promotes EGF-induced epithelial-to-mesenchymal transition and migration in gastric cancer cells by upregulating ZEB1 and ZEB2 through AKT
Lei Zhao et al.
CELL BIOLOGY INTERNATIONAL (2018)
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
T. R. J. Evans et al.
ANNALS OF ONCOLOGY (2017)
Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Michael J. Kelley et al.
CANCER INVESTIGATION (2017)
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P. D'Angelo et al.
CLINICAL CANCER RESEARCH (2017)
Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling
Tian Lan et al.
EXPERIMENTAL CELL RESEARCH (2017)
Structural and functional insights into the interaction between the Cas family scaffolding protein p130Cas and the focal adhesion-associated protein paxillin
Chi Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways
Yi-Hua Lai et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity
Yong Teng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
miR-140-5p suppresses the proliferation, migration and invasion of gastric cancer by regulating YES1
Zheng Fang et al.
MOLECULAR CANCER (2017)
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer
L. P. Stabile et al.
ORAL ONCOLOGY (2017)
A pathology atlas of the human cancer transcriptome
Mathias Uhlen et al.
SCIENCE (2017)
LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis
Elaine Ngan et al.
NATURE COMMUNICATIONS (2017)
TRIB1 promotes colorectal cancer cell migration and invasion through activation MMP-2 via FAK/Src and ERK pathways
Yuhui Wang et al.
ONCOTARGET (2017)
FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition
Yetunde Ogunbolude et al.
ONCOTARGET (2017)
Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling
Amy R. Dwyer et al.
CANCERS (2017)
Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression
Sungjin Kim et al.
CANCER RESEARCH (2017)
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer
Christine M. Parseghian et al.
CLINICAL CANCER RESEARCH (2017)
A Phase 2 Trial of Dasatinib in Patients With Locally Advanced or Stage IV Mucosal, Acral, or Vulvovaginal Melanoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2607)
Kevin Kalinsky et al.
CANCER (2017)
Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer
Julie E. Bauman et al.
JCI INSIGHT (2017)
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
Scott M. Schuetze et al.
CANCER (2016)
Saracatinib as a Metastasis Inhibitor in Metastatic Castration-Resistant Prostate Cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study
Edwin M. Posadas et al.
PROSTATE (2016)
A novel nuclear Src and p300 signaling axis controls migratory and invasive behavior in pancreatic cancer
David Paladino et al.
ONCOTARGET (2016)
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)
T. Powles et al.
ANNALS OF ONCOLOGY (2016)
Phase II studies of two different schedules of dasatinib in bone metastasis predominant metastatic breast cancer: SWOG S0622
Anne F. Schott et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
Zahi Mitri et al.
CLINICAL CANCER RESEARCH (2016)
Suppression of SRC Signaling Is Effective in Reducing Synergy between Glioblastoma and Stromal Cells
Alessia Calgani et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Src as a Therapeutic Target in Biliary Tract Cancer
Ah-Rong Nam et al.
MOLECULAR CANCER THERAPEUTICS (2016)
FYN promotes breast cancer progression through epithelial-mesenchymal transition
Ye-Gong Xie et al.
ONCOLOGY REPORTS (2016)
Bakuchiol suppresses proliferation of skin cancer cells by directly targeting Hck, Blk, and p38 MAP kinase
Jong-Eun Kim et al.
ONCOTARGET (2016)
Micro-Environmental Stress Induces Src-Dependent Activation of Invadopodia and Cell Migration in Ewing Sarcoma
Kelly M. Bailey et al.
NEOPLASIA (2016)
A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies
Matthew A. Gubens et al.
LUNG CANCER (2015)
Src family kinases differentially influence glioma growth and motility
Laura J. Lewis-Tuffin et al.
MOLECULAR ONCOLOGY (2015)
Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and Metastasis
Adriano Azevedo Mello et al.
PLOS ONE (2015)
Tissue-based map of the human proteome
Mathias Uhlen et al.
SCIENCE (2015)
Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells
Tanushree Chatterji et al.
ONCOTARGET (2015)
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis
Sebastien Tabaries et al.
ONCOTARGET (2015)
Focal adhesion kinase-dependent focal adhesion recruitment of SH2 domains directs SRC into focal adhesions to regulate cell adhesion and migration
Jui-Chung Wu et al.
SCIENTIFIC REPORTS (2015)
Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
S. J. Isakoff et al.
BRITISH JOURNAL OF CANCER (2014)
Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer
Lajos Pusztai et al.
CLINICAL CANCER RESEARCH (2014)
A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non-Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium
Scott A. Laurie et al.
CLINICAL LUNG CANCER (2014)
Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis
Simona Delle Monache et al.
EXPERIMENTAL CELL RESEARCH (2014)
The role of Src family kinases in growth and migration of glioma stem cells
Xiaosi Han et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer
John H. Strickler et al.
INVESTIGATIONAL NEW DRUGS (2014)
Phosphatase CD45 Both Positively and Negatively Regulates T Cell Receptor Phosphorylation in Reconstituted Membrane Protein Clusters
Gabriela Furlan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
Beverly Moy et al.
ONCOLOGIST (2014)
A Phase I/II Study Combining Erlotinib andDasatinib for Non-Small Cell Lung Cancer
Kathryn A. Gold et al.
ONCOLOGIST (2014)
Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer
Beverly Moy et al.
ONCOLOGIST (2014)
Role of c-Src activity in the regulation of gastric cancer cell migration
Yun Yang et al.
ONCOLOGY REPORTS (2014)
The Inhibition of Src Family Kinase Suppresses Pancreatic Cancer Cell Proliferation, Migration, and Invasion
Dong Wook Je et al.
PANCREAS (2014)
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
Catherine Wilson et al.
ONCOTARGET (2014)
Src as the link between inflammation and cancer
Sandy T. Liu et al.
FRONTIERS IN PHYSIOLOGY (2014)
Phosphorylation of unique domains of Src family kinases
Irene Amata et al.
FRONTIERS IN GENETICS (2014)
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
Przemyslaw W. Twardowski et al.
ANTI-CANCER DRUGS (2013)
In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma
Jia-Shing Chen et al.
BIOINFORMATICS (2013)
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
George Somlo et al.
CLINICAL CANCER RESEARCH (2013)
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours
Yasuhito Fujisaka et al.
INVESTIGATIONAL NEW DRUGS (2013)
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors
David S. Hong et al.
INVESTIGATIONAL NEW DRUGS (2013)
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma
Tara C. Gangadhar et al.
INVESTIGATIONAL NEW DRUGS (2013)
Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung
Andrew M. Brunner et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
John C. Araujo et al.
LANCET ONCOLOGY (2013)
Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
Cheng Ean Chee et al.
ONCOLOGIST (2013)
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
M. Campone et al.
ANNALS OF ONCOLOGY (2012)
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study
Rosemary A. Hannon et al.
BONE (2012)
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma
A. P. Algazi et al.
BRITISH JOURNAL OF CANCER (2012)
Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours
S. Kaye et al.
BRITISH JOURNAL OF CANCER (2012)
Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors
Adil I. Daud et al.
CLINICAL CANCER RESEARCH (2012)
A Phase I Trial of Dasatinib, an Src-Family Kinase Inhibitor, in Combination with Paclitaxel and Carboplatin in Patients with Advanced or Recurrent Ovarian Cancer
Angeles Alvarez Secord et al.
CLINICAL CANCER RESEARCH (2012)
Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and Metastasis
Christine M. Chan et al.
CLINICAL CANCER RESEARCH (2012)
Src-mediated regulation of E-cadherin and EMT in pancreatic cancer
Nagaraj S. Nagathihalli et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2012)
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer
Daniel J. Renouf et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
Tanja Trarbach et al.
INVESTIGATIONAL NEW DRUGS (2012)
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium
Helen J. Mackay et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
Athanassios Argiris et al.
INVESTIGATIONAL NEW DRUGS (2012)
Src-mediated phosphorylation of mammalian Abp1 (DBNL) regulates podosome rosette formation in transformed fibroblasts
Lindsy R. Boateng et al.
JOURNAL OF CELL SCIENCE (2012)
MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression
C. Oneyama et al.
ONCOGENE (2012)
A phase I study of dasatinib and weekly paclitaxel for metastatic breast cancer
M. N. Fornier et al.
ANNALS OF ONCOLOGY (2011)
Phase 2 Study of Dasatinib in the Treatment of Head and Neck Squamous Cell Carcinoma
Heather D. Brooks et al.
CANCER (2011)
A Phase 2 Trial of Dasatinib in Advanced Melanoma
Harriet M. Kluger et al.
CANCER (2011)
Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors
Shunji Takahashi et al.
CANCER SCIENCE (2011)
Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast Cancer
Ayca Gucalp et al.
CLINICAL BREAST CANCER (2011)
A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer
Erica L. Mayer et al.
CLINICAL CANCER RESEARCH (2011)
Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing
Christina I. Herold et al.
CLINICAL CANCER RESEARCH (2011)
Crosstalk between activated and inactivated c-Src in hepatocellular carcinoma
Mei-Lin Chen et al.
DISEASE MARKERS (2011)
Phosphorylation of Ser 21 in Fyn Regulates its Kinase Activity, Focal Adhesion Targeting, and Is Required for Cell Migration
Myeong Gu Yeo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
Melissa L. Johnson et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells
Florence Sancier et al.
PLOS ONE (2011)
Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
Evan Y. Yu et al.
UROLOGY (2011)
Inhibition of epithelial to mesenchymal transition in metastatic breast carcinoma cells by c-Src suppression
Xiang Liu et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2010)
Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non-Small-Cell Lung Cancer
Eric B. Haura et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Dasatinib in Patients With Advanced Non-Small-Cell Lung Cancer
Faye M. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Elevated c-Src and c-Yes expression in malignant skin cancers
Jang Hyun Lee et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Epithelial-Mesenchymal Transition in Cancer: Parallels Between Normal Development and Tumor Progression
Douglas S. Micalizzi et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2010)
c-Src-Mediated Phosphorylation of NoxA1 and Tks4 Induces the Reactive Oxygen Species (ROS)-Dependent Formation of Functional Invadopodia in Human Colon Cancer Cells
Davide Gianni et al.
MOLECULAR BIOLOGY OF THE CELL (2010)
Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition
Wataru Okamoto et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study
Primo N. Lara et al.
ANTI-CANCER DRUGS (2009)
Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Function
Eun-Kyoung Yim et al.
CANCER CELL (2009)
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
Evan Y. Yu et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
George D. Demetri et al.
CLINICAL CANCER RESEARCH (2009)
Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation
Matthew Oser et al.
JOURNAL OF CELL BIOLOGY (2009)
An integrin αvβ3-c-Src oncogenic unit promotes anchorage-independence and tumor progression
Jay S. Desgrosellier et al.
NATURE MEDICINE (2009)
Src kinases as therapeutic targets for cancer
Lori C. Kim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
N-WASP and Cortactin Are Involved In Invadopodium-Dependent Chemotaxis to EGF In Breast Tumor Cells
Vera DesMarais et al.
CELL MOTILITY AND THE CYTOSKELETON (2009)
Targeting src family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model
Serk In Park et al.
CANCER RESEARCH (2008)
Focal adhesion kinase is not required for Src-induced formation of invadopodia in KM12C colon cancer cells and can interfere with their assembly
Sebastien Vitale et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2008)
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines
Alex J. Eustace et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in Osteoclasts
Olivier Destaing et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Inhibition of Src Family Kinases with Dasatinib Blocks Migration and Invasion of Human Melanoma Cells
Ralf Buettner et al.
MOLECULAR CANCER RESEARCH (2008)
Src phosphorylation of cortactin enhances actin assembly
Shandiz Tehrani et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia
Emily S. Clark et al.
CANCER RESEARCH (2007)
Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: Rationale for patient selection and efficacy monitoring
Xi-De Wang et al.
GENOME BIOLOGY (2007)
Pyrazolo[3,4-d]pyrimidines c-Src inhibitors reduce epidermal growth factor-induced migration in prostate cancer cells
Adriano Angelucci et al.
EUROPEAN JOURNAL OF CANCER (2006)
Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis
G Chakraborty et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: Defining the stages of invadopodia formation and function
VV Artym et al.
CANCER RESEARCH (2006)
Inhibition of Src expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model
JG Trevino et al.
AMERICAN JOURNAL OF PATHOLOGY (2006)
Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases
YP Chong et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2005)
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells
S Nam et al.
CANCER RESEARCH (2005)
C-terminal Src kinase (CSK) and CSK-homologous kinase (CHK)-endogenous negative regulators of Src-family protein kinases
YP Chong et al.
GROWTH FACTORS (2005)
Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin
H Yamaguchi et al.
JOURNAL OF CELL BIOLOGY (2005)
Shp2 regulates Src family kinase activity and Ras/Erk activation by controlling Csk recruitment
SQ Zhang et al.
MOLECULAR CELL (2004)
Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays
LJ Lombardo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Structure and regulation of Src family kinases
TJ Boggon et al.
ONCOGENE (2004)
The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged
Q Ding et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness
H Ito et al.
SURGERY (2003)
Positive and negative regulation of T-cell activation through kinases and phosphatases
T Mustelin et al.
BIOCHEMICAL JOURNAL (2003)
Differential regulation of cell motility and invasion by FAK
DA Hsia et al.
JOURNAL OF CELL BIOLOGY (2003)
Src family kinases in tumor progression and metastasis
JM Summy et al.
CANCER AND METASTASIS REVIEWS (2003)
Substrate conformational restriction and CD45-catalyzed dephosphorylation of tail tyrosine-phosphorylated Src protein
DX Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Specific dephosphorylation of the Lck tyrosine protein kinase at Tyr-394 by the SHP-1 protein-tyrosine phosphatase
GG Chiang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines
JD Bjorge et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Selected glimpses into the activation and function of Src kinase
JD Bjorge et al.
ONCOGENE (2000)
Role of Src expression and activation in human cancer
RB Irby et al.
ONCOGENE (2000)
Development of T-leukaemias in CD45 tyrosine phosphatase-deficient mutant lck mice
M Baker et al.
EMBO JOURNAL (2000)
Src family tyrosine kinases and growth factor signaling
CL Abram et al.
EXPERIMENTAL CELL RESEARCH (2000)
Tissue specific expression of Yrk kinase: implications for differentiation and inflammation
M Martins-Green et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2000)
分享论文
